Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model

Pharmacology Biochemistry and Behavior

Volumn 73, Issue 4, 2002, Pages 901-910

  Yang, Jun ^a   Klaidman, Lori K ^a   Chang, Mei Ling ^a   Kem, Seyha ^a   Sugawara, Taku ^b   Chan, Pak ^b   Adams Jr , James D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dose response; Infarct volume; Limit; Neurological deficit; Nicotinamide; Time course

Indexed keywords

DNA; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; BRAIN NECROSIS; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ENERGY RESOURCE; ENZYME ACTIVITY; ISCHEMIA; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; APOPTOSIS; BRAIN; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NECROSIS; NIACINAMIDE; RATS; RATS, WISTAR;

EID: 0036830401     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00939-5     Document Type: Article

References (44)

1. Adams J.D., Mukherjee S.K., Klaidman L.K., Chang M.L., Yasharel R. Apoptosis and oxidative stress in the aging brain. Ann. N.Y. Acad. Sci. 786:1996;135-151.
2. Adams J.D., Klaidman L.K., Morales M., Moran K., Schiavoni B., Hsu J.R., Mukherjee S.K. Nicotinamide and neuroprotection. Bondy S.C. Chemicals and neurodegenerative disease. 1999;231-261 Prominent Press, Scottsdale.
3. Albanese J., Arnaud S., Rey M., Thomachot L., Alliez B., Martin C. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology. 87:1997;1328-1334.
4. Ayoub I.A., Maynard K.I. Therapeutic window for nicotinamide following transient focal cerebral ischemia. NeuroReport. 13:2002;213-216.
5. Ayoub I.A., Lee J., Ogilvy C.S., Beal M.F., Maynard K.I. Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci. Lett. 259:1999;21-24.
6. 10 and nicotinamide block striatal lesion produced by the mitochondrial toxin malonate. Ann. Neurol. 36:1994;882-888.
7. Belayev L., Alonso O.F., Busto R., Zhao W., Ginsberg M.D. Middle cerebral artery occlusion in the rat by intraluminal suture. Stroke. 27:1996;1616-1623.
8. Birkmayer J.G.D. Coenzyme nicotinamide adenine dinucleotide new therapeutic approach for improving dementia of the Alzheimer's type. Ann. Clin. Lab. Sci. 26:1996;1-9.
9. Birkmayer J.G.D., Vrecko C., Volc D., Birkmayer W. Nicotinamide adenine dinucleotide a new therapeutic approach to Parkinson's disease. Acta Neurol. Scand. 87:1993;32-35.
10. Braslavskii V.E., Shchavelev V.A., Kryzhanoskii G.N. Effect of nicotinamide on focal and generalized epileptic activity in the cerebral cortex. Bull. Exp. Biol. Med. 94:1982;39-42.
11. Brazda F.G., Coulson R.A. Toxicity of nicotinic acid and some of its derivatives. Proc. Soc. Exp. Biol. Med. 62:1946;19-20.
12. Brown S.L., Ewing J.R., Kolozsvary A., Butt S., Cao Y., Kim J.H. Magnetic resonance imaging of perfusion in rat cerebral 9L tumor after nicotinamide administration. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;627-633.
13. Chumakov V.N., Starchik T.G. Effect of nucleotide anti-aggregants (NAD, AMP) and ischemia on the tissue blood coagulation factors. Gematol. Transfuziol. 36:1991;9-13.
14. Du C., Hu R., Csernansky C.A., Hsu C.Y., Choi D.W. Very delayed infraction after mild focal cerebral ischemia: a role for apoptosis? J. Cereb. Blood Flow Metab. 16:1996;195-201.
15. Ellinger P., Fraenkel G., Abdel Kader M.M. The utilization of nicotinamide derivatives and related compounds by mammals, insects and bacteria. Biochem. J. 41:1947;559-568.
16. Henning S.M., McKee R.W., Swendseid M.E. Hepatic poly(ADP-ribose) polymerase activity in methyl donor deficient rats. J. Nutr. 119:1989;1431-1528.
17. Horsman M.R., Hoyer M., Honess D.F., Dennis I.F., Overgaard J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27:1993;131-139.
18. Huang S.L., Chao C.C. The effect of niacinamide on cerebral circulation. Proc. Soc. Exp. Biol. Med. 105:1960;551-553.
19. Kang-Lee Y.A., Mckee R.W., Wright S.M., Swendseid M.E., Jenden D.J., Jope R.S. Metabolic effects of nicotinamide administration in rats. J. Nutr. 113:1983;215-221.
20. + prevents apoptosis in the mouse brain induced by tertiary-butylhydroperoxide. Neurosci. Lett. 206:1996;5-8.
21. Klaidman L.K., Mukherjee S.K., Adams J.D. Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide. Biochim. Biophys. Acta. 1525:2000;136-148.
22. Kryzhanovskii G.N., Shandra A.A., Makul'kin R.F. Effect of nicotinamide on epileptic activity in the cerebral cortex. Bull. Exp. Biol. Med. 89:1980;37-41.
23. Lin S.H., Vincent A., Shaw T., Maynard K.I., Maiese K. Prevention of nitric oxide induced neuronal injury through the modulation of independent pathways of programmed cell death. J. Cereb. Blood Flow Metab. 20:2000;1380-1391.
24. Lo E.H., Bosque-Hamilton P., Meng W. Inhibition of poly(ADP-ribose) ploymerase reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation. Stroke. 29:1998;830-836.
25. Maiese K., Lin S.H., Chong Z.Z. Elucidating neuronal and vascular injury through the cytoprotective agent nicotinamide. Curr. Med. Chem. Immunol. Endocrinol. Metab. Agents. 1:2001;257-267.
26. Mokudai T., Ayoub I.A., Sakakibara Y., Lee E.J., Ogilvy C.S., Maynard K.I. Delayed treatment with nicotinamide improves neurological outcome and reduces infract volume after transient focal cerebral ischemia in Wistar rats. Stroke. 31:2000;1679-1685.
27. Morimoto T., Globus M.Y.T., Busto R., Martinez E., Ginsburg M.D. Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 16:1996;92-99.
28. Mukherjee S.K., Klaidman L.K., Yasharel R., Adams J.D. Increased brain NAD prevents neuronal apoptosis in vivo. Eur. J. Pharmacol. 30:1997;27-34.
29. Orser B.A., Pennefather P.S., MacDonald J.F. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 86:1997;903-917.
30. Patt A., Harken A.H., Burton L.K., Rodell T.C., Piermattei D., Schorr W.J., Parker N.B., Berger E.M., Horesch I.R., Terada L.S., Linas S.L., Cheronis J.C., Repine J.E. Xanthine oxidase derived hydrogen peroxide contributes to ischemia reperfusion induced edema in gerbil brains. J. Clin Invest. 81:1988;1556-1562.
31. Pfenninger E., Himmelseher S. Neuroprotection by ketamine at the cellular level. Anaesthesiology. 46(Suppl 1):1997;S47-S54.
32. Qin Z. A review of therapeutic potentials in ischemic stroke. Eur. Neurol. 39(Suppl 1):1998;21-25.
33. Ridenour T.R., Warner D.S., Todd M.M., Baker M.T. Effects of ketamine on outcome from temporary middle cerebral artery occlusion in the spontaneously hypertensive rat. Brain Res. 565:1991;116-122.
34. 3) reduced the infarct volume following permanent focal cerebral ischemia in female Sprague-Dawley and Wistar rats. Neurosci. Lett. 281:2000;111-114.
35. Sandstrom B.E., Marklund S.L. Effects of variation in glutathione peroxidase activity on DNA damage and cell survival in human cells exposed to hydrogen peroxide and t-butylhydroperoxide. Biochem. J. 271:1990;17-23.
36. Sato S., Tominaga T., Ohnishi T., Ohnishi S.T. Role of nitric oxide in brain ischemia. Ann. N.Y. Acad. Sci. 738:1994;369-373.
37. Soonthon-Brant V., Patel P.M., Drummond J.C., Cole D.J., Kelly P.J., Watson M. Fentanyl does not increase brain injury after focal cerebral ischemia in rats. Anesth. Analg. 88:1999;49-55.
38. Spandou E., Karkavelas G., Soubasi V., Avgovstides-Savvopoulou P., Loizidis T., Guiba-Tziampiri O. Effect of ketamine on hypoxic-ischemic brain damage in newborn rats. Brain Res. 819:1999;1-7.
39. Spector R. Niacin and niacinamide transport in the central nervous system. In vivo studies. J. Neurochem. 33:1979;895-904.
40. Sun A., Cheng J. Neuroprotective effects of poly (ADP-ribose) polymerase inhibitors in transient focal cerebral ischemia of rats. Acta Pharmacol. Sin. 19:1998;104-208.
41. Unna K. Studies on the toxicity and pharmacology of nicotinic acid. J Pharmacol. Exp. Ther. 65:1939;95-103.
42. Yabuki M., Inai Y., Yoshioka T., Hamazaki K., Yasuda T., Inoue M., Utsumi K. Oxygen dependent fragmentation of cellular DNA by nitric oxide. Free Radic. Res. 26:1997;245-255.
43. Yang G.Y., Chen S.F., Kinouchi H., Chan P.H., Weinstein P.R. Edema, cation content and ATPase activity after middle cerebral artery occlusion in rats. Stroke. 23:1992;1331-1336.
44. Zhang J., Dawson V.L., Dawson T.M., Snyder S.H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 263:1994;687-689.